CVS to Pay $315 Million to Settle Opioid Dispensing Lawsuit

CVS Pharmacy Inc. and its subsidiaries have agreed to pay $315 million to resolve a Justice Department case alleging the company unlawfully dispensed medically unnecessary prescriptions for highly addictive opioids. The settlement addresses a lawsuit filed in 2024 that accused the healthcare company of prescribing massive amounts of opioids and other controlled substances to increase profits at the expense of public health and safety.

This agreement represents the latest effort by the federal government to hold companies accountable for their alleged role in fueling the U.S. addiction and overdose crisis. Associate Attorney General Stanley Woodward stated that the settlement is a significant step in the Justice Department's efforts to combat the opioid epidemic by cracking down on pharmacies that unlawfully fulfill prescriptions for controlled substances.

CVS has maintained that its pharmacists are trained in the safe and appropriate use of all medications and that the company has implemented programs to aid pharmacists in making the best decisions for patients. However, the company stated that it strongly disagrees with the claims made in the lawsuit and that the settlement does not constitute an admission of wrongdoing. CVS also argued that pharmacists were being held to vague standards when filling prescription opioids.

The lawsuit, filed under the Biden administration, alleged that CVS violated the Controlled Substances Act by filling illegitimate prescriptions for high doses of potent opioids, which contributed to dependence and addiction. The Justice Department further alleged that the company dispensed large quantities of opioids based on prescriptions from providers known as "pill mills," which distribute drugs without a legitimate medical purpose.

According to the lawsuit, insufficient staffing levels, combined with performance metrics and incentive compensation policies, led pharmacists to rapidly fill prescriptions without verifying their legitimacy. These prescriptions were often billed to and reimbursed by Medicaid and other federal healthcare programs.

Under the terms of the settlement, CVS is required to implement additional safeguards to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate, according to Assistant Attorney General Brett Shumate.

Over the past decade, various companies, including drugmakers, wholesalers, and pharmacies, have agreed to settlements with U.S. governments totaling more than $50 billion. Much of this funding is designated to address the opioid crisis, which has been linked to a significant number of deaths in the U.S. annually, though recent figures show a sharp decline. While most of these settlements have been with state and local governments, the U.S. government has also reached several agreements, including with Walgreens and Walmart in recent years.